detailed diagnostic and prognostic categorization. Recently published gene expression and proteomic profiling data indicate new candidate molecules involved in melanoma pathogenesis, which are currently validated. This ongoing process of biomarker identification and validation results in a rapidly changing molecular view and classification of cutaneous malignancies, which holds the promise of improving not only our prognostic classification systems, but also our diagnostic and therapeutic potential. This article provides an overview of the currently known serologic and immunohistochemical biomarker in melanoma.
Introduction
Melanoma is the form of skin cancer with the highest death toll in the United States and Europe. Besides morphological and histopathologic biomarkers (anatomic site and type of the primary tumor, tumor size and invasion depth, ulceration, vascular invasion, and mitotic index), an increasing variety of molecular markers have been identified that provide the possibility of a more der and age, mitotic rate, tumor thickness, and ulceration. Additional variables that aid in assigning patients to specific risk groups include immunohistochemistry, gene expression profiling, comparative genomic hybridization, and mutational analysis.
For diagnostic purposes, a small panel of melanocytic lineage markers (S100, MART-1, and gp100/HMB45) is sufficient to distinguish melanoma from other types of nonmelanocytic cancers. However, no marker has proven useful in distinguishing spindle cell and desmoplastic melanomas from other tumors. Ki67 remains the most useful adjunct in distinguishing benign from malignant melanocytic tumors. 1 For prognostic classification, the situation is more complex. The transformation from benign melanocytes to metastatic melanoma is the result of a compilation of genetic alterations contributing to the hallmarks of cancer: uncontrolled proliferation, unlimited replicative potential, apoptosis resistance, and invasion. Several marker molecules involved in these genetic alterations have been identified, and their expression in primary melanoma has been studied and correlated with prognosis. Table 1 summarizes currently established biomarkers whose abnormal expression is associated with the patient's prognosis. It is possible that the most detailed prognostic classification will be based on a panel of multiple biomarkers rather than just one biomarker on this list.
In a recent retrospective study, primary melanomas (for which a long-term clinical follow-up was available) were analyzed using a cDNA expression microarray. 21 The authors described a signature of 174 genes to identify patients at risk of developing distant metastasis. From these genes, 141 were underexpressed and 33 overexpressed in tumors whose host remained free of metastasis for 4 years. Of these 174 genes, 30 had been already studied in melanoma; these genes are involved in cell cycle regulation (CKS2, CDC2, CCNB1, CENPF, and DHFR), mitosis (HCAP-G and STK6), mitotic spindle checkpoint (BUB1), inhibition (BIRC5) or stimulation (GPR105) of apoptosis, DNA replication (TOP2A, RRM2, TYMS, PCNA, MCM4, and MCM6), stress response (GLRX2, DNAJA1, HSPA4, HSPA5, HSPD1, and TXNIP), ubiquitin cycle (SIP), actin and calmodulin binding (CNN3), intracellular signaling (STMN2), negative regulation of the Wnt signaling pathway (CTNNBIP1), inhibition of MITF expression (EMX2), regulation of proteolysis (TNA), testis cancer (CML66), and metastasis suppression (NME1). The authors speculated that by means of antibodies covering the encoded proteins, it would be possible to improve the estimation of prognosis of melanoma patients and thereby allow treatment stratification. Particularly, determination of karyopherin alpha 2, minichromosome maintenance proteins (MCMs), geminin, and PCNA could be used to screen for melanoma patients with a poor clinical outcome.
Similarly, genetic abnormalities have recently been recognized to influence the prognosis of cancer patients. A new classification system has been proposed by Curtin et al 43, 44 and Viros et al 45 that combines genetic aberrations with histomorphologic characteristics, resulting in new insights into the pathogenesis of this malignancy.
Moreover, the chemosensitivity profile determined by an in vitro ATP-based chemosensitivity assay has been shown to differentiate between chemosensitive and chemoresistant melanoma patients and can be used as a biomarker of chemotherapy response and survival outcome. A phase II study testing this assay in 53 metastatic melanoma patients followed by a sensitivitydirected individualized chemotherapy demonstrated that the chemosensitivity profile of an individual patient, reflected by the best individual chemosensitivity index (BICSI), correlated with therapy outcome. 46 Interestingly, a surprisingly high proportion (42%) of the investigated patient cohort were classified as chemosensitive, and the remaining 58% were classified as chemoresistant. The objective response rate was 36.4% in chemosensitive patients compared to 16.1% in chemoresistant patients (P = .114). Progression arrest (complete response, partial response, and stable disease) was 59.1% vs 22.6% (P = .01). Chemosensitive patients showed an increased overall survival of 14.6 months compared with 7.4 months in chemoresistant patients (P = .041).
Serologic Markers
Despite a large research effort, the prognosis of metastasized melanoma is still poor; best results have been achieved in cases when the tumor is still amendable to surgical intervention. Thus, the search for reliable methods that will not only detect metastases in such early states, but also identify patients with high risk of disease progression who should undergo more vigorous follow-up is important. Serological markers for tumor progression combine several advantages such as the ease of obtaining serum samples and the availability of numerous methods to detect respective small molecules or proteins correlated with the tumor burden; hence, several serological biomarkers have been established. In several European countries, the melanocyte lineage/differentiation antigens S100-beta and melanoma inhibitory activity (MIA) are frequently or almost routinely used for early detection of tumor relapse or metastasis during follow-up of melanoma patients (Table 2) . Both proteins are with high but not exclusive specificity expressed by melanoma cells, and both correlate with the patient's tumor load.
The S100 protein is a 21-kd thermo-labile acidic dimeric protein that was originally isolated from central nervous system. It consists of two subunits, alpha and beta, in any pairing, ie, alpha/alpha, alpha/beta, and beta/beta. It affects the assembly and disassembly of microtubules and also interacts in a calcium-dependent manner with the p53 tumor suppressor gene. The beta subunit is expressed in cells of the central nervous system and of the melanocytic lineage. Initially, the presence of S100-beta in the cerebrospinal fluid was used as a marker of central nervous system damage. 78 In the following years, it was observed that S100-beta was also elevated in the serum of melanoma patients. 47 MIA was originally detected in melanoma cell culture supernatant 52 and was shown to exert an important role in cell-matrix interaction and metastasis. 53 Studies comparing both serum markers demonstrated that S100-beta is superior to MIA as an early indicator of tumor progression, relapse, or metastasis 79,50 ; hence S100-beta is used more often. 80 Both markers have been shown to be useful prognostic markers in melanoma patients with distant metastases 48, 49 but they fail to provide prognostic significance in early stages of melanoma, especially in patients who are tumor-free after surgical procedures. 54 Moreover, S100-beta fails to identify patients with lymph node micrometastases detected by sentinel node procedure. 81 The correlation of S100 serum concentrations with the patient's tumor load, however, makes it a useful marker for monitoring therapy response in the patient with advanced metastatic melanoma. 49 The strongest prognostic serum biomarker in advanced metastatic melanoma is lactate dehydrogenase (LDH), an unspecific marker indicating high tumor load in a variety of tumor entities, including melanoma. Studies comparing LDH, S100-beta, and MIA using multivariate data analysis showed LDH as the strongest independent prognostic factor in stage IV melanoma patients. 79 Due to its high prognostic significance paired with its easy, cost-efficient, and widely distributed detection methodology, serum LDH is the only Table 2 .
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Serologic Marker References
Melanocyte lineage/differentiation antigens S100-beta Guo et al 47 Schultz et al 48 Hauschild et al 49 Krähn et al 50 Garbe et al 51 MIA (melanoma inhibitory activity) Bogdahn et al 52 Blesch et al 53 Stahlecker et al 54 Garbe et al 51 
Tyrosinase
Agrup et al 55 molecular marker that has been included into the current melanoma staging and classification system of the American Joint Committee on Cancer (AJCC). 82 In fact, it serves as a stratification parameter in most randomized clinical trials testing therapeutic interventions in advanced melanoma, and it also can be used to monitor therapy response in these patients.
5-S-cysteinyldopa
Several reports suggest that a variety of additional potential biomarkers present in the serum may be correlated with tumor load and disease progression in melanoma. These are ascribed to different characteristic of melanoma such as melanocytic differentiation (eg, tyrosinase), tumor angiogenesis (eg, VEGF, bFGF, IL-8), cell adhesion and motility (eg, ICAM-1, MMPs), cytokines and their receptors (eg, IL-6, IL-10), antigen presentation (eg, HLA molecules), tumor cell metabolism (eg, TuM2-PK), and apoptosis (eg, Fas/CD95) ( Table  2 ). However, none of these markers has been demonstrated to be superior to S100-beta or LDH in reflecting the prognosis of patients in advanced disease stages. Moreover, these markers failed to be of prognostic relevance in early-stage tumor-free patients.
An innovative approach to identify new and better serological biomarkers in melanoma is the serum proteomic profiling. This methodology offers the possibility to screen the whole serum proteome for markers that match different criteria such as prognostic significance and prediction of therapy response. Using this technology, marker proteins from thematic fields different from those mentioned above might be found and thereafter validated for their clinical use. The first promising results showed that patients with stage I and stage IV disease can be differentiated by their serum proteomic profiles. 83 A recent study using proteomic profiling in larger sets of sera succeeded in the identification of serum amyloid A as a new prognostic serum biomarker in melanoma. 84 
Conclusions
Melanoma is a highly aggressive form of skin cancer that is difficult to treat once the tumor has metastasized beyond the locoregional area. Recently established biomarkers such as morphological and histopathologic characteristics, as well as molecular markers, allow a detailed diagnostic and prognostic categorization that is mandatory for stratified or even personalized therapy.
